Details of Research Outputs

TitleStructure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator
Author (Name in English or Pinyin)
Luo, G.1,2; Lin, X.1,2; Li, Z.3; Xiao, M.1,2; Li, X.4; Zhang, D.3; Xiang, H.1,2
Date Issued2021
Source PublicationEuropean Journal of Medicinal Chemistry
ISSN02235234
DOI10.1016/j.ejmech.2020.112910
Education discipline科技类
Published range国外学术期刊
Volume Issue Pages卷: 209
References
[1] Han, C.Y., Update on FXR biology: promising therapeutic target?. Int. J. Mol. Sci., 19, 2018, 2069.
[2] Chiang, J.Y.L., Bile acids: regulation of synthesis. J. Lipid Res. 50 (2009), 1955–1966.
[3] Makishima, M., Okamoto, A.Y., Repa, J.J., Tu, H., Learned, R.M., Luk, A., Hull, M.V., Lustig, K.D., Mangelsdorf, D.J., Shan, B., Identification of a nuclear receptor for bile acids. Science 284 (1999), 1362–1365.
[4] Zhu, Y., Liu, H., Zhang, M., Guo, G.L., Fatty liver diseases, bile acids, and FXR. Acta Pharm. Sin. B 6 (2016), 409–412.
[5] Goodwin, B., Jones, S.A., Price, R.R., Watson, M.A., McKee, D.D., Moore, L.B., Galardi, C., Wilson, J.G., Lewis, M.C., Roth, M.E., Maloney, P.R., Willson, T.M., Kliewer, S.A., A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6 (2000), 517–526.
[6] Modica, S., Gadaleta, R.M., Moschetta, A., Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal., 8, 2010, e005.
[7] Jonker, J.W., Liddle, C., Downes, M., FXR and PXR: potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol. 130 (2012), 147–158.
[8] Wang, H., He, Q., Wang, G., Xu, X., Hao, H., FXR modulators for enterohepatic and metabolic diseases. Expert Opin. Ther. Pat. 28 (2018), 765–782.
[9] Moris, D., Giaginis, C., Tsourouflis, G., Theocharis, S., Farnesoid-X receptor (FXR) as a promising pharmaceutical target in atherosclerosis. Curr. Med. Chem. 24 (2017), 1147–1157.
[10] Keitel, V., Dröge, C., Häussinger, D., Targeting FXR in cholestasis. Handb. Exp. Pharmacol. 256 (2019), 299–324.
[11] Gege, C., Kinzel, O., Steeneck, C., Schulz, A., Kremoser, C., Knocking on FXR's door: the “hammerhead”-structure series of FXRs agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr. Top. Med. Chem. 14 (2014), 2143–2158.
[12] Xu, Y., Recent progress on bile acid receptor modulators for treatment of metabolic diseases. J. Med. Chem. 59 (2016), 6553–6579.
[13] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., Dasarathy, S., Diehl, A.M., Hameed, B., Kowdley, K.V., McCullough, A., Terrault, N., Clark, J.M., Tonascia, J., Brunt, E.M., Kleiner, D.E., Doo, E., Farnesoid X nuclear receptor ligand obeticholic acid for non cirrhotic, non-alcoholic steatohepatitis (flint): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
[14] Younossi, Z.M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q.M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P.N., Sheridan, D., Sheikh, M.Y., Trotter, J., Knapple, W., Lawitz, E., F Abdelmalek, M., Kowdley, K.V., Montano-Loza, A.J., Boursier, J., Mathurin, P., Bugianesi, E., Mazzella, G., Olveira, A., Cortez-Pinto, H., Graupera, I., Orr, D., Gluud, L.L., Dufour, J., Shapiro, D., Campagna, J., Zaru, L., MacConell, L., Shringarpure, R., Harrison, S., Sanyal, A.J., Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394 (2019), 2184–2196.
[15] Alemi, F., Kwon, E., Poole, D.P., Lieu, T., Lyo, V., Cattaruzza, F., Cevikbas, F., Steinhoff, R., Nassini, R., Materazzi, S., Guerrero-Alba, R., Valdez-Morales, E., Cottrell, G.S., Schoonjans, K., Geppetti, P., Vanner, S.J., Bunnett, N.W., Corvera, C.U., The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123 (2013), 1513–1530.
[16] Gioiello, A., Cerra, B., Mostarda, S., Guercini, C., Pellicciari, R., Macchiarulo, A., Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. Curr. Top. Med. Chem. 14 (2014), 2159–2174.
[17] Massafra, V., Pellicciari, R., Gioiello, A., van Mil, S.W.C., Progress and challenges of selective Farnesoid X Receptor modulation. Pharmacol. Ther. 191 (2018), 162–177.
[18] Carotti, A., Marinozzi, M., Custodi, C., Cerra, B., Pellicciari, R., Gioiello, A., Macchiarulo, A., Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands. Curr. Top. Med. Chem. 14 (2014), 2129–2142.
[19] Fiorucci, S., Mencarelli, A., Distrutti, E., Zampella, A., Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med. Chem. 4 (2012), 877–891.
[20] Maloney, P.R., Parks, D.J., Haffner, C.D., Fivush, M., Chandra, G., Plunket, K.D., Creech, K.L., Moore, L.B., Wilson, J.G., Lewis, M.C., Jones, S., Willson, T.M., Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 43 (2000), 2971–2974.
[21] Masuda, A., Gohda, K., Iguchi, Y., Fujimori, K., Yamashita, Y., Oda, K., Une, M., Teno, N., N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR). Bioorg. Med. Chem., 28, 2020, 115512.
[22] Genin, M.J., Bueno, A.B., Francisco, J.A., Manninen, P.R., Bocchinfuso, W.P., Montrose-Rafizadeh, C., Cannady, E.A., Jones, T.M., Stille, J.R., Raddad, E., Reidy, C., Cox, A., Michael, M.D., Michael, L.F., Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid: a novel FXR agonist for the treatment of dyslipidemia. J. Med. Chem. 58 (2015), 9768–9772.
[23] Bass, J.Y., Caravella, J.A., Chen, L., Creech, K.L., Deaton, D.N., Madauss, K.P., Marr, H.B., McFadyen, R.B., Miller, A.B., Mills, W.Y., Navas, F., Parks, D.J., Smalley, T.L., Spearing, P.K., Todd, D., Williams, S.P., Wisely, G.B., Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg. Med. Chem. Lett 21 (2011), 1206–1213.
[24] Tully, D.C., Rucker, P.V., Chianelli, D., Williams, J., Vidal, A., Alper, P.B., Mutnick, D., Bursulaya, B., Schmeits, J., Wu, X.D., Bao, D.J., Zoll, J., Kim, Y., Groessl, T., McNamara, P., Seidel, H.M., Molteni, V., Liu, B., Phimister, A., Joseph, S.B., Laffitte, B., Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J. Med. Chem. 60 (2017), 9960–9973.
[25] Bowlus, C., Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepatic Med. 8 (2016), 89–95.
[26] Pencek, R., Marmon, T., Roth, J.D., Liberman, A., Hooshmand-Rad, R., Young, M.A., Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes. Metabol. 18 (2016), 936–940.
[27] Lee, E.A., Lee, D.I., Kim, H.Y., Ahn, S.H., Seong, H.R., Jung, W.H., Kim, K.Y., Kim, S., Rhee, S.D., Cyp7a1 is continuously increased with disrupted fxr-mediated feedback inhibition in hypercholesterolemic TALLYHO/jng mice. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1863 (2018), 20–25.
[28] Duan, Y.T., Zhang, F., Yuan, W.Z., Wei, Y.H., Wei, M.M., Zhou, Y., Yang, Y.Q., Chang, Y., Wu, X.A., Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf 15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats. Life Sci., 232, 2019, 116638.
[29] Merk, D., Steinhilber, D., Schubert-Zsilavecz, M., Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med. Chem. 4 (2012), 1015–1036.
[30] Merk, D., Lamers, C., Ahmad, K., Gomez, R.C., Schneider, G., Steinhilber, D., Schubert-zsilavecz, M., Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. J. Med. Chem. 57 (2014), 8035–8055.
[31] Chianelli, D., Rucker, P.V., Roland, J., Tully, D.C., Nelson, J., Liu, X.D., Bursulaya, B., Hernandez, E.D., Wu, J., Prashad, M., Schlama, T., Liu, Y., Chu, A., Schmeits, J., Huang, D.J., Hill, R., Bao, D., Zoll, J., Kim, Y., Groessl, T., McNamara, P., Liu, B., Richmond, W., Sancho-Martinez, I., Phimister, A., Seidel, H.M., Badman, M.K., Joseph, S.B., Laffitte, B., Molteni, V., Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis. J. Med. Chem. 63 (2020), 3868–3880.
[32] Schmidt, J., Rotter, M., Weiser, T., Wittmann, S., Weizel, L., Kaiser, A., Heering, J., Goebel, T., Angioni, C., Wurglics, M., Paulke, A., Geisslinger, G., Kahnt, A., Steinhilber, D., Proschak, E., Merk, D., A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis. J. Med. Chem. 60 (2017), 7703–7724.
[33] Sepe, V., Distrutti, E., Fiorucci, S., Zampella, A., Farnesoid X receptor modulators 2014-present: a patent review. Expert Opin. Ther. Pat. 28 (2018), 351–364.
[34] Qiu, R.M., Luo, G.S., Cai, X.R., Liu, L.Y., Chen, M.Q., Chen, D.Y., You, Q.D., Xiang, H., Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities. Bioorg. Med. Chem. Lett 28 (2018), 3726–3730.
[35] Ghosh, A.K., Brindisi, M., Urea derivatives in modern drug discovery and medicinal chemistry. J. Med. Chem. 63 (2020), 2751–2788.
[36] Merk, D., Steinhilber, D., Schubert-Zsilavecz, M., Characterizing ligands for farnesoid X receptor – available in vitro test systems for farnesoid X receptor modulator development. Expet Opin. Drug Discov. 9 (2014), 27–37.
[37] Costantino, G., Entrena-Guadix, A., Macchiarulo, A., Gioiello, A., Pellicciari, R., Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding. J. Med. Chem. 48 (2005), 3251–3259.
[38] Luan, Z.L., Huo, X.K., Dong, P.P., Tian, X.G., Sun, C.P., Lv, X., Feng, L., Ning, J., Wang, C., Zhang, B.J., Ma, X.C., Highly potent non-steroidal FXR agonists protostane-type triterpenoids: structure-activity relationship and mechanism. Eur. J. Med. Chem., 182, 2019, 111652.
[39] Huo, X.K., Liu, J., Yu, Z.L., Wang, Y.F., Wang, C., Tian, X.G., Ning, J., Feng, L., Sun, C.P., Zhang, B.J., Ma, X.C., Alisma orientale extract exerts the reversing cholestasis effect by activation of farnesoid X receptor. Phytomedicine 42 (2018), 34–42.
[40] Kainuma, M., Makishima, M., Hashimoto, Y., Miyachi, H., Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. Bioorg. Med. Chem. 15 (2007), 2587–2600.
[41] Flesch, D., Gabler, M., Lill, A., Carrasco Gomez, R., Steri, R., Schneider, G., Stark, H., Schubert-Zsilavecz, M., Merk, D., Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties. Bioorg. Med. Chem. 23 (2015), 3490–3498.
Citation statistics
Cited Times:7[WOS]   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
Identifierhttps://irepository.cuhk.edu.cn/handle/3EPUXD0A/1757
CollectionSchool of Science and Engineering
Corresponding AuthorZhang, D.; Xiang, H.
Affiliation
1.State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China
2.Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
3.Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, 210009, China
4.School of Life and Health Sciences and Warshel Institute for Computational Biology, The Chinese University of Hong Kong, Shenzhen, Guangdong, China
Recommended Citation
GB/T 7714
Luo, G.,Lin, X.,Li, Z.et al. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator[J]. European Journal of Medicinal Chemistry,2021.
APA Luo, G., Lin, X., Li, Z., Xiao, M., Li, X., .. & Xiang, H. (2021). Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator. European Journal of Medicinal Chemistry.
MLA Luo, G.,et al."Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator".European Journal of Medicinal Chemistry (2021).
Files in This Item:
There are no files associated with this item.
Related Services
Usage statistics
Google Scholar
Similar articles in Google Scholar
[Luo, G.]'s Articles
[Lin, X.]'s Articles
[Li, Z.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Luo, G.]'s Articles
[Lin, X.]'s Articles
[Li, Z.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Luo, G.]'s Articles
[Lin, X.]'s Articles
[Li, Z.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.